BRPI0408999A - comprimidos prensados de multiparticulados de liberação oral prolongada - Google Patents

comprimidos prensados de multiparticulados de liberação oral prolongada

Info

Publication number
BRPI0408999A
BRPI0408999A BRPI0408999-5A BRPI0408999A BRPI0408999A BR PI0408999 A BRPI0408999 A BR PI0408999A BR PI0408999 A BRPI0408999 A BR PI0408999A BR PI0408999 A BRPI0408999 A BR PI0408999A
Authority
BR
Brazil
Prior art keywords
release
compressed tablets
therapeutic agent
compressed
agglutinating
Prior art date
Application number
BRPI0408999-5A
Other languages
English (en)
Inventor
Robert M Noack
John M Heimlich
Ernest J Lee
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BRPI0408999A publication Critical patent/BRPI0408999A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPRIMIDOS PRENSADOS DE MULTIPARTICULADOS DE LIBERAçãO ORAL PROLONGADA". A presente invenção refere-se a uma formulação multiparticulada de um agente terapêutico de liberação prolongada, em que as partículas dos núcleos revestidos do multiparticulado do agente terapêutico são sobrerevestidas com um agente de aglutinação-dispersão, tal como povidona ou povidona reticulada. A invenção é também dirigida a comprimidos prensados da formulação de multiparticulado de liberação prolongada da invenção, e a um método de administração oral dos comprimidos prensados de clindamicina a um sujeito para tratar ou prevenir uma infecção deste com bactérias gram-positivas. O agente de aglutinação-dispersão nas formulações da presente invenção assegura que os comprimidos prensados formados a partir daquelas permanecem intactos através da administração oral, e se dissolvem pouco tempo depois, permitindo que os multiparticulados liberem o agente terapêutico contido neles durante um período de tempo prolongado.
BRPI0408999-5A 2003-04-04 2004-03-29 comprimidos prensados de multiparticulados de liberação oral prolongada BRPI0408999A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46085103P 2003-04-04 2003-04-04
PCT/IB2004/001117 WO2004087175A1 (en) 2003-04-04 2004-03-29 Oral extended release compressed tablets of multiparticulates

Publications (1)

Publication Number Publication Date
BRPI0408999A true BRPI0408999A (pt) 2006-03-28

Family

ID=33131934

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408999-5A BRPI0408999A (pt) 2003-04-04 2004-03-29 comprimidos prensados de multiparticulados de liberação oral prolongada

Country Status (7)

Country Link
US (1) US20040228915A1 (pt)
EP (1) EP1613333A1 (pt)
JP (1) JP2006522099A (pt)
BR (1) BRPI0408999A (pt)
CA (1) CA2520321A1 (pt)
MX (1) MXPA05010636A (pt)
WO (1) WO2004087175A1 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
WO2004047718A2 (en) * 2002-11-28 2004-06-10 Themis Laboratories Private Limited Process for manufacturing sustained release microbeads containing venlafaxine hci
EP1617832B1 (en) 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
AU2004261143B2 (en) * 2003-07-25 2009-11-05 Allergan Pharmaceuticals International Limited A doxycycline metal complex in a solid dosage form
ME00391B (me) 2003-08-08 2011-10-10 Biovail Laboratories Int Srl Tableta bupropion hidrohlorida sa modifikovanim otpuštanjem
AU2011244902B2 (en) * 2004-08-13 2012-09-27 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
EA200700388A1 (ru) * 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
HRP20100682T4 (hr) 2004-08-13 2014-08-01 Boehringer Ingelheim International Gmbh Formulacija tablete produljenog oslobađanja koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu sol, postupak njezine priprave i uporaba
WO2006046256A1 (en) * 2004-10-27 2006-05-04 Alembic Limited Extended release formulation of pramipexole dihydrochloride
JP2008525313A (ja) 2004-12-27 2008-07-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬の安定化方法
AU2006206359B2 (en) * 2005-01-21 2011-03-31 Allergan Pharmaceuticals International Limited A tetracycline metal complex in a solid dosage form
JP2008530185A (ja) * 2005-02-21 2008-08-07 フラメル・テクノロジー ロサルタンの経口医薬剤形態
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
FR2882259A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan
FR2884145A1 (fr) * 2005-04-06 2006-10-13 Flamel Technologies Sa Forme pharmaceutique orale de losartan
FR2882522B1 (fr) 2005-02-25 2007-04-13 Aventis Pharma Sa Composition pharmaceutique solide comprenant de la telithromycine
KR101213345B1 (ko) * 2005-04-28 2012-12-17 에자이 알앤드디 매니지먼트 가부시키가이샤 항치매약을 함유하는 조성물
WO2007002518A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
CN101534808A (zh) * 2005-06-27 2009-09-16 拜维尔实验室国际有限公司 丁氨苯丙酮盐的改良释放配制品
US8221792B2 (en) 2005-07-07 2012-07-17 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
DK1954241T3 (da) * 2005-11-28 2012-06-18 Orexigen Therapeutics Inc Zonisamid-formulering med vedvarende frigivelse
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
US9023400B2 (en) * 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008001311A2 (en) * 2006-06-26 2008-01-03 Ranbaxy Laboratories Limited Pharmaceutical composition containing fixed dose combination of atenolol with isosorbide mononitrate
WO2008038155A2 (en) * 2006-07-25 2008-04-03 Intelgenx Corp. Controlled-release pharmaceutical tablets
US7674479B2 (en) * 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
US8703191B2 (en) 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
GB0616794D0 (en) * 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
WO2008062446A2 (en) * 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
DK2089005T3 (da) 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
WO2008068778A2 (en) * 2006-12-05 2008-06-12 Alembic Limited Extended release pharmaceutical composition of pramipexole
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
DE102008048729A1 (de) * 2008-09-24 2010-03-25 Add Technologies Ltd Advanced Drug Delivery Multipartikuläre Tabletten und Verfahren zur deren Herstellung
EP2385769A4 (en) * 2008-12-15 2014-08-20 Valeant Pharmaceuticals Luxembourg S R L QUICKLY SOLUBLE VITAMIN FORMULATION AND METHOD FOR THEIR USE
EP2253306A1 (en) * 2009-05-18 2010-11-24 Royal College of Surgeons in Ireland Orodispersible dosage forms containing solid drug dispersions
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
JP2013526601A (ja) 2010-05-24 2013-06-24 ルピン・リミテッド プラミペキソールの徐放性製剤
GB201020895D0 (en) * 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form
CN102579384B (zh) * 2011-01-17 2015-09-02 杭州赛利药物研究所有限公司 别嘌醇缓释微丸片及其制备方法
JP2014516080A (ja) * 2011-06-08 2014-07-07 エスティーアイ ファーマ， エルエルシー 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
CN110893181A (zh) 2012-06-06 2020-03-20 纳丙药业有限责任公司 治疗超重和肥胖症的方法
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
CN107875136B (zh) * 2017-12-27 2021-03-05 广州白云山医药集团股份有限公司白云山制药总厂 一种阿莫西林药物制剂及其制备方法
CN113350315B (zh) * 2021-06-10 2022-09-06 黑龙江澳利达奈德制药有限公司 一种别嘌醇缓释胶囊及其制备方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3586600T2 (de) * 1984-02-10 1993-02-18 Benzon Pharma As Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend.
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
SE9201930D0 (sv) * 1992-06-24 1992-06-24 Astra Ab Gastric antibacterial treatment
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5484608A (en) * 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US5780055A (en) * 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
GB9620709D0 (en) * 1996-10-04 1996-11-20 Danbiosyst Uk Colonic delivery of weak acid drugs
CA2290624C (en) * 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
WO1999001121A1 (en) * 1997-07-01 1999-01-14 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
DK1083885T3 (da) * 1998-06-11 2007-02-26 Pharmacia & Upjohn Co Llc Delavirdintabletformulering
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
EP1126826B3 (en) * 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
DE60204897T2 (de) * 2001-08-28 2006-05-11 Pharmacia Corp. Kristalline freie base von clindamycin

Also Published As

Publication number Publication date
CA2520321A1 (en) 2004-10-14
US20040228915A1 (en) 2004-11-18
JP2006522099A (ja) 2006-09-28
WO2004087175A1 (en) 2004-10-14
EP1613333A1 (en) 2006-01-11
MXPA05010636A (es) 2005-12-12

Similar Documents

Publication Publication Date Title
BRPI0408999A (pt) comprimidos prensados de multiparticulados de liberação oral prolongada
BRPI0518266A2 (pt) medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BR0110420A (pt) Agonistas muscarìnicos
WO2005011655A3 (en) Pyridazine derivatives and their use as therapeutic agents
BRPI0403935A (pt) Formas de dosagem de azitromicina com efeitos colaterais reduzidos
WO2003039436A3 (es) Composiciones farmaceuticas que contienen oxibutinina
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
MX9605940A (es) Compuestos bioaromaticos que llevan un grupo adamantilo en orto, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
BR0316279A (pt) Compostos orgânicos
BRPI0313148B8 (pt) formulações sólidas matriciais de lamotrigina contendo revestimento externo e perfuração em tal revestimento
BRPI0411098A (pt) benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos
JP2006516571A5 (pt)
DE69718734D1 (de) Bicyclische aromatische verbindungen
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
BR0014946A (pt) Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
BR9809694A (pt) Processo e composição para administração de taxanos oralmente a pacientes humanos
BR0015149A (pt) Método e composições para administração de taxanos oralmente a pacientes humanos
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BR0308229A (pt) Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.